ArticleMycotoxin research2026
Chlorella sorokiniana attenuates deoxynivalenol-exacerbated allergic dermatitis and type 2 immune responses in mice.
Article in Mycotoxin research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic dietary exposure to low concentrations of deoxynivalenol (DON), a trichothecene mycotoxin found in cereal products, disrupts immune homeostasis and exacerbates allergic inflammation. Chlorella sorokiniana (CS) can adsorb DON and reduce its systemic absorption. However, whether this DON-binding activity protects against DON-induced immune dysregulation remains unclear. Here, we investigated the effects of CS on DON-induced toxicity and DON-exacerbated allergic dermatitis. In vitro, murine DC2.4 dendritic cells were exposed to DON in the presence or absence of CS-treated DON preparations. DON reduced cell viability and ATP-dependent luminescence while increasing IL-1β and TNFα production in a concentration-dependent manner. Pretreatment with CS attenuated these cytotoxic and pro-inflammatory effects. In vivo, chronic low-dose DON exposure aggravated toluene diisocyanate-induced allergic dermatitis, as demonstrated by increased ear swelling, scratching behavior, inflammatory cell infiltration, dermal edema, and cutaneous expression of Il4, Il13, and Il33. DON also increased dendritic, activated CD4
Indexed as
Identifiers
42886313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.